RTTNews | Nov 27, 2020 07:04AM EST

07:04 Friday, November 27, 2020 (RTTNews.com) - Protalix BioTherapeutics, Inc. (PLX) and Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., announced the FDA has extended the PDUFA date for review of the Biologics License Application seeking accelerated approval of pegunigalsidase alfa (PRX-102) for the proposed treatment of adult patients with Fabry disease. The BLA submission includes a set of preclinical, clinical, and manufacturing data compiled from the phase I/II clinical trial of pegunigalsidase alfa.

The FDA extended the PDUFA action date by three months to April 27, 2021, from January 27, 2021.

Read the original article on RTTNews ( https://www.rttnews.com/3149062/protalix-fda-extends-pdufa-action-date-for-pegunigalsidase-alfa-quick-facts.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2020 RTTNews.com All Rights Reserved